niacinamide has been researched along with Asthenia in 10 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Asthenia: Clinical sign or symptom manifested as debility, or lack or loss of strength and energy.
Excerpt | Relevance | Reference |
---|---|---|
"Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC)." | 7.83 | [Implementation of a nurse-driven educational program improves management of sorafenib's toxicities in hepatocellular carcinoma]. ( Boucher, E; Brunot, A; Crouzet, L; Duval, M; Edeline, J; Guillygomarc'h, A; Laguerre, B; Le Roy, F; Le Sourd, S; Lelievre, N; M'Sadek, A; Ventroux, E, 2016) |
"Sorafenib is the standard of care for advanced hepatocellular carcinoma (HCC)." | 7.81 | Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. ( Boucher, E; Brunot, A; Cattenoz, C; Crouzet, L; Edeline, J; Gédouin, D; Guillygomarc'h, A; Larible, C; Latournerie, M; Le Roy, F; Le Sourd, S, 2015) |
"Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC)." | 3.83 | [Implementation of a nurse-driven educational program improves management of sorafenib's toxicities in hepatocellular carcinoma]. ( Boucher, E; Brunot, A; Crouzet, L; Duval, M; Edeline, J; Guillygomarc'h, A; Laguerre, B; Le Roy, F; Le Sourd, S; Lelievre, N; M'Sadek, A; Ventroux, E, 2016) |
"Sorafenib is the standard of care for advanced hepatocellular carcinoma (HCC)." | 3.81 | Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. ( Boucher, E; Brunot, A; Cattenoz, C; Crouzet, L; Edeline, J; Gédouin, D; Guillygomarc'h, A; Larible, C; Latournerie, M; Le Roy, F; Le Sourd, S, 2015) |
"One hundred patients with sleep disorders and asthenic syndrome of various etiology and severity were studied." | 2.90 | [Clinical efficacy of neurometabolic therapy of dissomical disorders in asthenic syndrome]. ( Esipov, AV; Ivolgin, AF; Kalyagin, IE; Karakozov, AG; Katenko, SV; Kazakov, SP; Khritinin, DF; Levchenko, OB; Molodova, AI, 2019) |
"Angiogenesis does not initiate malignancy but promotes tumor progression and metastasis." | 2.44 | [Oral drugs inhibiting the VEGF pathway]. ( Armand, JP; Mir, O; Ropert, S, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (20.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (10.00) | 29.6817 |
2010's | 7 (70.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Esipov, AV | 1 |
Ivolgin, AF | 1 |
Khritinin, DF | 1 |
Katenko, SV | 1 |
Kazakov, SP | 1 |
Karakozov, AG | 1 |
Kalyagin, IE | 1 |
Levchenko, OB | 1 |
Molodova, AI | 1 |
Castellano, D | 1 |
Capdevila, J | 1 |
Sastre, J | 1 |
Alonso, V | 1 |
Llanos, M | 1 |
García-Carbonero, R | 1 |
Manzano Mozo, JL | 1 |
Sevilla, I | 1 |
Durán, I | 1 |
Salazar, R | 1 |
Derbel Miled, O | 1 |
Dionne, C | 1 |
Terret, C | 1 |
Segura-Ferlay, C | 1 |
Flechon, A | 1 |
Neidhart, EM | 1 |
Negrier, S | 1 |
Droz, JP | 1 |
Polunina, AG | 1 |
Osinovskaia, NA | 1 |
Gudkova, AN | 1 |
Gekht, AB | 1 |
Edeline, J | 2 |
Crouzet, L | 2 |
Le Sourd, S | 2 |
Larible, C | 1 |
Brunot, A | 2 |
Le Roy, F | 2 |
Cattenoz, C | 1 |
Latournerie, M | 1 |
Gédouin, D | 1 |
Guillygomarc'h, A | 2 |
Boucher, E | 2 |
M'Sadek, A | 1 |
Duval, M | 1 |
Ventroux, E | 1 |
Lelievre, N | 1 |
Laguerre, B | 1 |
Suslina, ZA | 1 |
Klocheva, EG | 1 |
Piradov, MA | 1 |
Rumiantseva, SA | 1 |
Romantsov, MG | 1 |
Kovalenko, AL | 1 |
Ropert, S | 1 |
Mir, O | 1 |
Armand, JP | 1 |
Pietranera, P | 1 |
Chouinard, C | 1 |
1 review available for niacinamide and Asthenia
Article | Year |
---|---|
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Human | 2007 |
2 trials available for niacinamide and Asthenia
Article | Year |
---|---|
[Clinical efficacy of neurometabolic therapy of dissomical disorders in asthenic syndrome].
Topics: Administration, Oral; Antioxidants; Asthenia; Drug Combinations; Flavin Mononucleotide; Humans; Inos | 2019 |
Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asth | 2013 |
7 other studies available for niacinamide and Asthenia
Article | Year |
---|---|
Sorafenib and sunitinib for elderly patients with renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asthenia; Carcinoma, Renal Cell; Disease-Free Surviv | 2013 |
[Influence of cytoflavin on symptoms of asthenia, emotional disorders and autonomic regulation in patients with organic asthenic disorder].
Topics: Adult; Asthenia; Autonomic Nervous System; Drug Combinations; Emotions; Female; Flavin Mononucleotid | 2014 |
Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Asthenia; Carcinoma, Hepatocellular; Comorbid | 2015 |
[Implementation of a nurse-driven educational program improves management of sorafenib's toxicities in hepatocellular carcinoma].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Asthenia; Carcinoma, Hepatocellular; Diarrhea; Fe | 2016 |
[Efficacy of cytoflavin in the treatment of chronic cerebral ischemia].
Topics: Asthenia; Brain Ischemia; Chronic Disease; Drug Combinations; Flavin Mononucleotide; Humans; Inosine | 2010 |
[Therapeutic value of an association of phospholipids and adrenal cortex in hepatology].
Topics: Adolescent; Adrenal Cortex Hormones; Adrenal Glands; Adult; Aged; Asthenia; Biliary Tract Diseases; | 1971 |
[Asthenia in children].
Topics: Adolescent; Asthenia; Child; Child, Preschool; Fructosephosphates; Humans; Lysine; Niacinamide; Pare | 1973 |